cTACE or DEB-TACE+HAIC Combined With Regorafenib ± Anti-PD1 Antibody for uHCC

NCT05025592 · clinicaltrials.gov ↗

UNKNOWN

Status

60

Enrollment

OTHER

Sponsor class

Conditions

HCC
Transarterial Chemoembolization
Hepatic Arterial Infusion Chemotherapy
Regorafenib

Interventions

DRUG: Regorafenib
DEVICE: cTACE/DEB-TACE-HAIC

Sponsor

Peking University Cancer Hospital & Institute